Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02753530
Other study ID # STUDY00002461
Secondary ID R01FD004809
Status Completed
Phase Phase 2
First received
Last updated
Start date August 16, 2017
Est. completion date January 11, 2021

Study information

Verified date April 2023
Source ZevraDenmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.


Description:

A Phase 2/3, randomized, double-blind, placebo-controlled, international, 20-month intervention study in patients with IBM.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date January 11, 2021
Est. primary completion date January 11, 2021
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria: - Meet any of the European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 categories for IBM. - Demonstrate being able to arise from a chair without support from another person or device. - Able to ambulate at least 20 ft/6 meters with or without assistive device. Once arisen from the chair, participant may use any walking device, i.e. walker/frame, can, crutches, or braces. They cannot be supported by another person and cannot use furniture or wall for support. - Age at onset of weakness >45 years. - Body weight of >= 40 kg. - Able to give informed consent. Exclusion Criteria: - History of any of the following excludes subject participation in the study: chronic infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer less than five years prior; or other chronic serious medical illnesses. - Presence of any of the following on routine blood screening: White blood cells (WBC) <3000; platelets < 100,000; hematocrit <30%; blood urea nitrogen (BUN) >30 mg/dL; creatinine >1.5 x upper limit of normal; symptomatic liver disease with serum albumin <3 g/dL. - History of most recent creatine kinase >15x the upper limit of normal without any other explanation besides IBM. - History of non-compliance with other therapies. - Use of testosterone except for physiologic replacement doses in case of androgen deficiency. Participants must have documented proof of the androgen deficiency. - Coexistence of other disease that would be likely to affect outcome measures - Drug or alcohol abuse within past three months. - Participation in a recent drug study in the last 30 days prior to the screening visit or use of a biologic agent less than 6 months prior to the screening visit. - Women who are lactating or unwilling to use adequate method of birth control who are not surgically sterile. Adequate birth control includes use of intrauterine device, abstinence, or oral contraceptives or a double barrier method, e.g condom plus diaphragm will be necessary for both male and female participants. - Participants taking >7.5 mg prednisolone or equivalent or participants on Intravenous Immunoglobulin Therapy (IVIg) or other immunosuppressants within the last 3 months. - Clinically significant renal or hepatic disease, as indicated by clinical laboratory assessment.

Study Design


Intervention

Drug:
Arimoclomol
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Other:
Placebo
2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime

Locations

Country Name City State
United Kingdom University College of London London
United States University of Colorado School of Medicine Aurora Colorado
United States Johns Hopkins University Baltimore Maryland
United States Brigham and Women's Hospital Boston Massachusetts
United States University of Virginia Charlottesville Virginia
United States The Ohio State University Columbus Ohio
United States Nerve and Muscle Center of Texas Houston Texas
United States University of California, Irvine Irvine California
United States University of Kansas Medical Center Kansas City Kansas
United States Phoenix Neurological Associates Phoenix Arizona
United States University of Rochester Rochester New York
United States University of Utah Salt Lake City Utah

Sponsors (3)

Lead Sponsor Collaborator
ZevraDenmark University College, London, University of Kansas Medical Center

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10-item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person. Change from Baseline to Month 20
Secondary Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10-item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person. Change from Baseline to Month 12
Secondary Grip Strength Unilateral hand grip strength in both hands measured using the Jamar Dynamometer. Results are for the stronger limb, as identified at baseline. Change from Baseline to Month 12 and 20
Secondary Modified Timed up and go (mTUG) The patient's combined ability to rise from a chair and walk 3 meters, turn around and walk back to the chair and sit down. The test was performed twice and the fastest time was used. The results were expressed as velocity in meters/second. Change from Baseline to Month 12 and Month 20
Secondary Manual Muscle Testing (MMT), Total Score The Manual Muscle Testing (MMT) scores the strength of 24 muscles (axial, proximal, and distal muscles, tested bilaterally) on a scale from 0 to 10 points. The total score is calculated as an average across the 24 muscles and ranges from 0 to 10. The total score will increase if a patient is getting stronger and decrease if a patient is getting weaker. Change from Baseline to Month 12 and Month 20
Secondary 6 Minute Walk Test (6MWT); Distance After 6 Minutes (6MWD) The distance patients could walk in 6 minutes. The distance walked in meters was recorded after 6 minutes. Change from Baseline to Month 12 and Month 20
Secondary Short Form-36 (SF-36) Physical Component Score Measured using the Short Form health survey with 36 items (SF-36). The questionnaire measures 8 health concepts which yields 2 summary measures: physical and mental health. The physical component score includes 4 scales of physical functioning (10 items), role limitations due to physical health (4 items), bodily pain (2 items), and general health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100, and the summary measure is calculated as the average score. Higher scores indicate better health status. Change from Baseline to Month 12 and Month 20
Secondary Maximum Voluntary Isometric Contraction (MVICT) of Quadriceps Unilateral strength of the knee extensor muscles on both limbs using the MicroFET hand-held dynamometer. Results are for the stronger limb, as identified at baseline. Change from Baseline to Month 12 and Month 20
Secondary Health Assessment Questionnaire - Disability Index (HAQ-DI) The disability index of the HAQ measures self-reported functional status (disability) including the patient's use of aids or devices and/or help from other persons. The scale is composed of 20 items in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities). Each domain has at least 2 subcategory items, scored on a scale from 0 to 3, and for each of the 8 domains the domain score was the highest score of the involved subcategory scores. The total score reported is an average over 8 domains and scores from at least 6 domains had to be available for the total score to be calculated. The average total score ranges from 0 to 3, and a higher score corresponds to a worsening in functional status. Change from Baseline to Month 12 and Month 20
Secondary 2 Minute Walk Test (2MWT) The distance patients could walk in 2 minutes (during the 6 Minute Walk Test) recorded in meters. Change from Baseline to Month 12 and Month 20
Secondary Short Form-36 (SF-36) Mental Component Score Measured using the Short Form health survey with 36 items (SF-36). The questionnaire measures 8 health concepts which yields 2 summary measures: physical and mental health. The mental component score is composed of energy/fatigue (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and emotional well-being (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100, and the summary measure is calculated as the average score. Higher scores indicate better health status. Change from Baseline to Month 12 and Month 20
Secondary Patient Global Impression of Severity (PGIS) Patient-reported assessment of the impact of IBM on the ability to complete activities of daily living (e.g. dressing, walking, bathing) at the time of the assessment. The response options for the impact of IBM were "none" (i.e. no impact), "very mild", "mild", "moderate", "severe", and "very severe". Change from Baseline to Month 12 and Month 20
Secondary Patient Global Impression of Change (PGIC) Patient-reported assessment of the change from start of study treatment in the impact of IBM on the ability to complete activities of daily living (e.g. dressing, walking, bathing). The response options for change in impact were "very much worse", "much worse", "a little worse", "no change", "a little improved", "much improved", and "very much improved". Change from Baseline to Month 12 and Month 20
Secondary Clinician Global Impression of Severity (CGIS) Clinician-reported assessment of the severity of the patient's IBM symptoms at the time of the assessment. The response options were "none", "very mild", "mild", "moderate", "severe", and "very severe" Change from Baseline to Month 12 and Month 20
Secondary Clinician Global Impression of Change (CGIC) Clinician-reported assessment of the change from start of study treatment in the patient's IBM symptoms. The response options for change in IBM were "very much worse", "much worse", "a little worse", "no change", "a little improved", "much improved", and "very much improved". Change from Baseline to Month 12 and Month 20
Secondary Falls and Near Falls Falls and near falls registered by the participants in a diary Accumulated number from Baseline to Month 20
See also
  Status Clinical Trial Phase
Completed NCT00769860 - Arimoclomol in Sporadic Inclusion Body Myositis Phase 2/Phase 3
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Active, not recruiting NCT05046821 - Sporadic Inclusion Body Myositis Natural History Study
Recruiting NCT06153108 - Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting NCT04659031 - A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) Phase 1
Completed NCT03440034 - Study of Pioglitazone in Sporadic Inclusion Body Myositis Phase 1
Terminated NCT04049097 - Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial Phase 3
Completed NCT00001261 - Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Phase 2
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Completed NCT01734369 - Environmental Risk Factors for Myositis in Military Personnel
Active, not recruiting NCT04975841 - Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells N/A
Recruiting NCT00017914 - Adult and Juvenile Myositis
Completed NCT00917956 - Lithium in Inclusion Body Myositis (IBM) N/A
Completed NCT03633318 - Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Recruiting NCT04789070 - Phase III Trial of Sirolimus in IBM Phase 3
Active, not recruiting NCT05721573 - A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis Phase 2/Phase 3
Recruiting NCT05032131 - Cell Therapy for IBM by Muscle Injection of ADSVF Phase 1
Completed NCT03299335 - Molecular Profile of the Evolution of Inclusion Body Myositis N/A
Completed NCT04421677 - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Phase 1